Jane Street Group, LLC Ideaya Biosciences, Inc. Transaction History

Jane Street Group, LLC

$88.2 Billion
Q2 2024

A detailed history of Jane Street Group, LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 129,013 shares of IDYA stock, worth $3.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

129,013

Previous 29,778 333.25%

Holding current value

$3.97 Million

Previous $1.31 Million 246.78%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$34.37 - $43.46 $3.41 Million - $4.31 Million	99,235 Added 333.25%	129,013 $4.53 Million
Q1 2024 May 15, 2024	SELL	$34.2 - $47.13 $385,057 - $530,636	-11,259 Reduced 27.44%	29,778 $1.31 Million
Q4 2023 Feb 14, 2024	BUY	$24.59 - $35.83 $568,496 - $828,353	23,119 Added 129.03%	41,037 $1.46 Million
Q3 2023 Nov 14, 2023	SELL	$21.07 - $29.77 $911,635 - $1.29 Million	-43,267 Reduced 70.72%	17,918 $483,000
Q2 2023 Aug 14, 2023	SELL	$13.33 - $25.53 $26,620 - $50,983	-1,997 Reduced 3.16%	61,185 $1.44 Million
Q1 2023 May 15, 2023	BUY	$13.49 - $18.72 $667,701 - $926,565	49,496 Added 361.65%	63,182 $867,000
Q4 2022 Feb 14, 2023	BUY	$14.47 - $18.17 $198,036 - $248,674	13,686 New	13,686 $248,000
Q1 2022 May 17, 2022	SELL	$11.18 - $24.02 $171,735 - $368,971	-15,361 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$20.95 - $26.88 $321,812 - $412,903	15,361 New	15,361 $363,000
Q3 2020 Nov 17, 2020	SELL	$11.22 - $14.46 $140,855 - $181,530	-12,554 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$3.59 - $18.57 $45,068 - $233,127	12,554 New	12,554 $179,000

Others Institutions Holding IDYA

# of Institutions

206

Shares Held

73.6M

Call Options Held

21.5K

Put Options Held

20.3K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.48B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Ideaya Biosciences, Inc. Transaction History